Equity market conditions and a robust pipeline of filings support continued IPO activity through year-end 2026. Multiple issuers priced offerings in early October, including Retension Pharmaceuticals and TRex Bio, while others such as Iambic Therapeutics and City Therapeutics have set terms for mid-month listings on Nasdaq. Year-to-date U.S. traditional IPO proceeds have already surpassed full-year 2025 totals, driven by selectivity favoring profitable growth companies in biotech and AI-adjacent sectors. Key upcoming catalysts include potential November debuts for larger names like Anthropic and additional S-1 filings in the pipeline. Elevated Treasury yields near 5% and post-election uncertainty may influence timing, yet the volume of active registrations indicates near-term supply is unlikely to stall before January 2027.